302 related articles for article (PubMed ID: 27872102)
1. E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma.
Spector ME; Sacco AG; Bellile E; Taylor JMG; Jones T; Sun K; Brown WC; Birkeland AC; Bradford CR; Wolf GT; Prince ME; Moyer JS; Malloy K; Swiecicki P; Eisbruch A; McHugh JB; Chepeha DB; Rozek L; Worden FP
Clin Cancer Res; 2017 Jun; 23(11):2723-2729. PubMed ID: 27872102
[No Abstract] [Full Text] [Related]
2. Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer.
Fakhry C; Qualliotine JR; Zhang Z; Agrawal N; Gaykalova DA; Bishop JA; Subramaniam RM; Koch WM; Chung CH; Eisele DW; Califano J; Viscidi RP
Cancer Prev Res (Phila); 2016 Feb; 9(2):135-41. PubMed ID: 26701665
[TBL] [Abstract][Full Text] [Related]
3. Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma.
Hanna GJ; Sridharan V; Margalit DN; La Follette SK; Chau NG; Rabinowits G; Lorch JH; Haddad RI; Tishler RB; Anderson KS; Schoenfeld JD
Cancer Biomark; 2017; 19(2):129-136. PubMed ID: 28387659
[TBL] [Abstract][Full Text] [Related]
4. CD8
Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
[TBL] [Abstract][Full Text] [Related]
5. Molecular and serologic markers of HPV 16 infection are associated with local recurrence in patients with oral cavity squamous cell carcinoma.
Huang CG; Lee LA; Liao CT; Yen TC; Yang SL; Liu YC; Li JC; Gong YN; Kang CJ; Huang SF; Fang KH; Chang KP; Lee LY; Hsueh C; Shih SR; Tsao KC
Oncotarget; 2017 May; 8(21):34820-34835. PubMed ID: 28422732
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma.
Holzinger D; Wichmann G; Baboci L; Michel A; Höfler D; Wiesenfarth M; Schroeder L; Boscolo-Rizzo P; Herold-Mende C; Dyckhoff G; Boehm A; Del Mistro A; Bosch FX; Dietz A; Pawlita M; Waterboer T
Int J Cancer; 2017 Jun; 140(12):2748-2757. PubMed ID: 28316084
[TBL] [Abstract][Full Text] [Related]
7. HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study.
Economopoulou P; Koutsodontis G; Avgeris M; Strati A; Kroupis C; Pateras I; Kirodimos E; Giotakis E; Kotsantis I; Maragoudakis P; Gorgoulis V; Scorilas A; Lianidou E; Psyrri A
PLoS One; 2019; 14(5):e0215984. PubMed ID: 31071126
[TBL] [Abstract][Full Text] [Related]
8. Detection of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma using droplet digital polymerase chain reaction.
Biron VL; Kostiuk M; Isaac A; Puttagunta L; O'Connell DA; Harris J; Côté DW; Seikaly H
Cancer; 2016 May; 122(10):1544-51. PubMed ID: 26989832
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer.
Smith EM; Pawlita M; Rubenstein LM; Haugen TH; Hamsikova E; Turek LP
Int J Cancer; 2010 Jul; 127(1):111-7. PubMed ID: 19876924
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of HPV in head and neck squamous cell carcinoma.
Liang C; Marsit CJ; McClean MD; Nelson HH; Christensen BC; Haddad RI; Clark JR; Wein RO; Grillone GA; Houseman EA; Halec G; Waterboer T; Pawlita M; Krane JF; Kelsey KT
Cancer Res; 2012 Oct; 72(19):5004-13. PubMed ID: 22991304
[TBL] [Abstract][Full Text] [Related]
11. Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma.
Reder H; Taferner VF; Wittekindt C; Bräuninger A; Speel EM; Gattenlöhner S; Wolf G; Klussmann JP; Wuerdemann N; Wagner S
J Mol Diagn; 2020 Nov; 22(11):1333-1343. PubMed ID: 32822851
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
Lang Kuhs KA; Kreimer AR; Trivedi S; Holzinger D; Pawlita M; Pfeiffer RM; Gibson SP; Schmitt NC; Hildesheim A; Waterboer T; Ferris RL
Cancer; 2017 Nov; 123(22):4382-4390. PubMed ID: 28950407
[TBL] [Abstract][Full Text] [Related]
13. Comparison of peptide enzyme-linked immunosorbent assay and radioimmunoprecipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 proteins.
Sun Y; Shah KV; Müller M; Muñoz N; Bosch XF; Viscidi RP
J Clin Microbiol; 1994 Sep; 32(9):2216-20. PubMed ID: 7529250
[TBL] [Abstract][Full Text] [Related]
14. Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable.
Ren J; Xu W; Su J; Ren X; Cheng D; Chen Z; Bender N; Mirshams M; Habbous S; de Almeida JR; Perez-Ordonez B; Goldstein DP; Wang JR; Bratman SV; Huang SH; Jang R; Zhao Y; Waterboer T; Hung RJ; Liu G
Int J Cancer; 2020 Apr; 146(8):2166-2174. PubMed ID: 31269236
[TBL] [Abstract][Full Text] [Related]
15. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.
Rosales R; López-Contreras M; Cortes RR
J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939
[TBL] [Abstract][Full Text] [Related]
16. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M
Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419
[TBL] [Abstract][Full Text] [Related]
17. Markers of HPV infection and survival in patients with head and neck tumors.
Koslabova E; Hamsikova E; Salakova M; Klozar J; Foltynova E; Salkova E; Rotnaglova E; Ludvikova V; Tachezy R
Int J Cancer; 2013 Oct; 133(8):1832-9. PubMed ID: 23564321
[TBL] [Abstract][Full Text] [Related]
18. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
[TBL] [Abstract][Full Text] [Related]
19. Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients.
Nindl I; Benitez-Bribiesca L; Berumen J; Farmanara N; Fisher S; Gross G; Lopez-Carillo L; Müller M; Tommasino M; Vazquez-Curiel A
Arch Virol; 1994; 137(3-4):341-53. PubMed ID: 7524466
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection.
Beachler DC; Viscidi R; Sugar EA; Minkoff H; Strickler HD; Cranston RD; Wiley DJ; Jacobson LP; Weber KM; Margolick JB; Reddy S; Gillison ML; D'Souza G
Sex Transm Dis; 2015 Feb; 42(2):93-7. PubMed ID: 25585068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
